LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 13

Search options

  1. Article ; Online: ZBTB16::RARA variant acute promyelocytic leukemia (vAPL) treated with gemtuzumab ozogamicin (GO) with unique pathology and genetic findings.

    Kassem, Alaa M / Keinath, Melissa C / Adler, Jason A / Gadde, Ramya / Tomlinson, Benjamin K / Shetty, Shashirekha

    British journal of haematology

    2023  Volume 202, Issue 6, Page(s) 1077–1078

    MeSH term(s) Humans ; Leukemia, Promyelocytic, Acute/drug therapy ; Leukemia, Promyelocytic, Acute/genetics ; Leukemia, Promyelocytic, Acute/pathology ; Gemtuzumab/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal ; Aminoglycosides ; Leukemia, Myeloid, Acute ; Promyelocytic Leukemia Zinc Finger Protein
    Chemical Substances Gemtuzumab (93NS566KF7) ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal ; Aminoglycosides ; ZBTB16 protein, human (147855-37-6) ; Promyelocytic Leukemia Zinc Finger Protein
    Language English
    Publishing date 2023-07-26
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.18950
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: COVID-19 presenting as a viral exanthem and detected during admission prescreening in a hematopoietic cell transplant recipient.

    Ahmed, Nausheen / Lima, Marcos de / Rohr, Bethany R / Tomlinson, Benjamin K

    Hematology, transfusion and cell therapy

    2020  Volume 42, Issue 3, Page(s) 215–217

    Keywords covid19
    Language English
    Publishing date 2020-06-13
    Publishing country Brazil
    Document type Case Reports
    ISSN 2531-1387
    ISSN (online) 2531-1387
    DOI 10.1016/j.htct.2020.06.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Book ; Online: COVID-19 presenting as a viral exanthem and detected during admission prescreening in a hematopoietic cell transplant recipient

    Ahmed, Nausheen / Lima, Marcos de / Rohr, Bethany R. / Tomlinson, Benjamin K.

    Hematology, Transfusion and Cell Therapy v.42 n.3 2020

    2020  

    Keywords covid19
    Language English
    Publishing date 2020-09-01
    Publisher Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
    Publishing country br
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: COVID-19 presenting as a viral exanthem and detected during admission prescreening in a hematopoietic cell transplant recipient

    Ahmed, Nausheen / Lima, Marcos de / Rohr, Bethany R / Tomlinson, Benjamin K
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #597753
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: COVID-19 presenting as a viral exanthem and detected during admission prescreening in a hematopoietic cell transplant recipient

    Ahmed, Nausheen / Lima, Marcos de / Rohr, Bethany R. / Tomlinson, Benjamin K.

    Hematology, Transfusion and Cell Therapy

    2020  Volume 42, Issue 3, Page(s) 215–217

    Keywords covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ISSN 2531-1379
    DOI 10.1016/j.htct.2020.06.002
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia.

    Tomlinson, Benjamin K / Tuscano, Joseph M / Abedi, Mehrdad / Welborn, Jeanna / Arora, Mili / O'Donnell, Robert T / Wun, Ted / Jonas, Brian A

    American journal of hematology

    2019  Volume 94, Issue 11, Page(s) E291–E294

    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Doxorubicin/analogs & derivatives ; Febrile Neutropenia/chemically induced ; Female ; Humans ; Hydroxyurea/administration & dosage ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/drug therapy ; Male ; Middle Aged ; Neoplastic Cells, Circulating ; Polyethylene Glycols/administration & dosage ; Polyethylene Glycols/adverse effects ; Progression-Free Survival ; Proteasome Inhibitors/administration & dosage ; Proteasome Inhibitors/adverse effects ; Treatment Outcome
    Chemical Substances Proteasome Inhibitors ; liposomal doxorubicin ; Polyethylene Glycols (3WJQ0SDW1A) ; Bortezomib (69G8BD63PP) ; Doxorubicin (80168379AG) ; Hydroxyurea (X6Q56QN5QC)
    Language English
    Publishing date 2019-08-20
    Publishing country United States
    Document type Clinical Trial, Phase II ; Letter ; Research Support, N.I.H., Extramural
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.25605
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1251: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia.

    Wang, Jiasheng / de Lima, Marcos / Cooper, Brenda W / Boughan, Kirsten / Metheny, Leland / Otegbeye, Folashade / Caimi, Paolo F / Gallogly, Molly / Malek, Ehsan / Cao, Shufen / Fu, Pingfu / Glotzbecker, Brett / Schiltz, Nicholas K / Tomlinson, Benjamin K

    Leukemia & lymphoma

    2021  Volume 62, Issue 6, Page(s) 1450–1457

    Abstract: The role of filgrastim during acute myeloid leukemia (AML) induction therapy remains controversial. At our institution, newly diagnosed AML patients from 2003 through 2019 were retrospectively evaluated. Patients were stratified on whether they received ... ...

    Abstract The role of filgrastim during acute myeloid leukemia (AML) induction therapy remains controversial. At our institution, newly diagnosed AML patients from 2003 through 2019 were retrospectively evaluated. Patients were stratified on whether they received filgrastim within 5 days after early assessment bone marrow (BMBx) and divided into early GCSF group (eGCSF) and no-eGCSF group. A total of 121 patients were included. We found significantly shorter hospital stay (median 24 vs 26 days,
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biopsy ; Bone Marrow ; Filgrastim/therapeutic use ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy ; Remission Induction ; Retrospective Studies
    Chemical Substances Granulocyte Colony-Stimulating Factor (143011-72-7) ; Filgrastim (PVI5M0M1GW)
    Language English
    Publishing date 2021-01-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2020.1864350
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.

    Ali, Naveed / Sharma, Ashish Arunkumar / de Rezende, Ana Carolina Pires / Otegbeye, Folashade / Latif, Bilal Muhammad / Kerbauy, Mariana Nassif / Cooper, Brenda W / Sanchez, Gabriela / Metheny, Leland / Bal, Saswat K / Sakuraba, Roberto / Tomlinson, Benjamin K / Boughan, Kirsten M / Kerbauy, Lucila / Malek, Ehsan / Ribeiro, Andreza Feitosa / Gallogly, Molly / Mansur, David / Pereira, Gisele /
    Weltman, Eduardo / Sekaly, Rafick-Pierre / de Lima, Marcos / Caimi, Paolo F / Hamerschlak, Nelson

    Transplantation and cellular therapy

    2022  Volume 28, Issue 7, Page(s) 370.e1–370.e10

    Abstract: Reduced-intensity conditioning (RIC) regimens frequently provide insufficient disease control in patients with high-risk hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated intensification of ... ...

    Abstract Reduced-intensity conditioning (RIC) regimens frequently provide insufficient disease control in patients with high-risk hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated intensification of fludarabine/busulfan (Flu/Bu) RIC with targeted marrow irradiation (TMI) in a dose escalation with expansion phase I clinical trial. TMI doses were delivered at 1.5 Gy in twice daily fractions on days -10 through -7 (dose levels: 3 Gy, 4.5 Gy, and 6 Gy), Flu (30 mg/m
    MeSH term(s) Adolescent ; Adult ; Aged ; Bone Marrow ; Busulfan/therapeutic use ; Hematologic Neoplasms/therapy ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/etiology ; Transplantation, Homologous ; Vidarabine/analogs & derivatives
    Chemical Substances Vidarabine (FA2DM6879K) ; Busulfan (G1LN9045DK) ; fludarabine (P2K93U8740)
    Language English
    Publishing date 2022-04-11
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article
    ZDB-ID 3062231-1
    ISSN 2666-6367
    ISSN (online) 2666-6367
    DOI 10.1016/j.jtct.2022.04.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5082: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia.

    Tomlinson, Benjamin K / Gallogly, Molly M / Kane, Donna M / Metheny, Leland / Lazarus, Hillard M / William, Basem M / Craig, Michael D / Levis, Mark J / Cooper, Brenda W

    Clinical lymphoma, myeloma & leukemia

    2019  Volume 20, Issue 4, Page(s) 226–233.e1

    Abstract: Background: Midostaurin, a multikinase inhibitor, is approved for treatment of FLT3-mutant acute myeloid leukemia (AML). A phase I study established that midostaurin 75 mg orally twice daily for 14 days with standard dose azacitidine was safe and ... ...

    Abstract Background: Midostaurin, a multikinase inhibitor, is approved for treatment of FLT3-mutant acute myeloid leukemia (AML). A phase I study established that midostaurin 75 mg orally twice daily for 14 days with standard dose azacitidine was safe and tolerable in elderly patients with AML. Herein, we report the phase II expansion cohort of previously untreated elderly or unfit patients with AML.
    Patients and methods: Primary objectives were to further describe the toxicity profile and determine the response rate in untreated patients with AML. Patients received midostaurin 75 mg orally twice daily on days 8 to 21 in combination with intravenous azacitidine at 75 mg/m
    Results: Twenty-six patients (median age, 74 years; range, 59-85 years) with FLT3 wild-type AML were accrued. Patients received a median of 2 cycles of therapy (range, 1-10 cycles). Seven (29%) of 24 evaluable patients achieved a clinical response (4 complete response; 1 complete response with incomplete count recovery; and 2 partial response). The median overall survival was 244 days (95% confidence interval, 203-467 days). Hematologic, infectious, and gastrointestinal toxicities were comparable to similar studies. Peripheral blood FLT3 wild-type phosphorylation declined to 8% to 55% of pretreatment by day 15 of cycle 1 (7 patients) and declined with subsequent cycles (< 10% baseline) in 2 patients who were analyzed after cycle 3.
    Conclusion: Multiple cycles of azacitidine and midostaurin were not well-tolerated, but persistent inhibition of FLT3 wild-type phosphorylation suggest intermittent dosing of midostaurin should be considered in future low-intensity regimens for FLT3-mutant AML.
    MeSH term(s) Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Azacitidine/administration & dosage ; Female ; Humans ; Leukemia, Myeloid, Acute/blood ; Leukemia, Myeloid, Acute/drug therapy ; Male ; Middle Aged ; Staurosporine/administration & dosage ; Staurosporine/analogs & derivatives ; fms-Like Tyrosine Kinase 3/blood
    Chemical Substances FLT3 protein, human (EC 2.7.10.1) ; fms-Like Tyrosine Kinase 3 (EC 2.7.10.1) ; Staurosporine (H88EPA0A3N) ; midostaurin (ID912S5VON) ; Azacitidine (M801H13NRU)
    Language English
    Publishing date 2019-11-06
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2019.10.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.

    Garcia, Jacqueline S / Flamand, Yael / Penter, Livius / Keng, Michael / Tomlinson, Benjamin K / Mendez, Lourdes M / Koller, Paul / Cullen, Nicole / Arihara, Yohei / Pfaff, Kathleen / Wolff, Jacquelyn O / Brunner, Andrew M / Galinsky, Ilene / Bashey, Asad / Antin, Joseph H / Cutler, Corey / Ho, Vincent / Jonas, Brian A / Luskin, Marlise R /
    Wadleigh, Martha / Winer, Eric S / Savell, Alexandra / Leonard, Rebecca / Robertson, Taylor / Davids, Matthew S / Streicher, Howard / Rodig, Scott J / Ritz, Jerome / Wu, Catherine J / DeAngelo, Daniel J / Neuberg, Donna / Stone, Richard M / Soiffer, Robert J

    Blood

    2022  Volume 141, Issue 15, Page(s) 1884–1888

    MeSH term(s) Humans ; Decitabine/therapeutic use ; Ipilimumab/adverse effects ; Myelodysplastic Syndromes/drug therapy ; Azacitidine/therapeutic use ; Leukemia, Myeloid, Acute/drug therapy
    Chemical Substances Decitabine (776B62CQ27) ; Ipilimumab ; Azacitidine (M801H13NRU)
    Language English
    Publishing date 2022-10-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2022017686
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top